Background and Purpose: Combined perfusion and oxygen metabolism PET imaging is highly predictive of spontaneous outcome after middle cerebral artery (MCA) stroke, independent of clinical scores, but whether the assessment of perfusion alone by SPECT provides similar information remains unclear. We have assessed the prognostic value of 99mTc-HMPAO-SPECT at the acute stage of stroke. Methods: Twenty-seven first-ever nonhemorrhagic MCA territory stroke patients were prospectively studied 4–20 h (mean: 12 h) after onset with 99mTc-HMPAO-SPECT. None was part of a therapeutic trial or received thrombolysis. Neurological deficits were quantified at admission and 2 months later with Orgogozo’s MCA scale. SPECT images were visually classified by 3 independent observers into one of three patterns, as follows: pattern I = marked and extensive tracer hypofixation; pattern II = moderate and/or focal hypofixation with or without combined hyperfixation, and pattern III = normal or increased uptake without hypofixation. In addition to this visual analysis, we also calculated a voxel-based ‘hypoperfusion score’, an index of severity × extent of hypofixation according to Mountz’s method. Results: There was a good intra- and interobserver agreement. After consensus, 9, 14 and 4 patients were classified in patterns I, II and III, respectively. These patterns had a significant predictive value for raw outcome but not for percentage recovery (p = 0.008 and p = 0.127, respectively). Thus, all patients in pattern III had a good outcome, while most (but not all) patients in pattern I had a poor or intermediate outcome; pattern II patients were more evenly distributed among outcomes. Hypoperfusion scores were highly significantly positively correlated with both 2-month outcomes and percentage recoveries, even after controlling the predictive value of day 0 MCA scores by partial correlations. Comments: We found that SPECT had a significant added predictive value even when compared to admission neurological scores. Although less accurate than PET, 99mTc-HMPAO-SPECT may help to predict spontaneous individual neurological evolution, especially whenever perfusion images are normal or show an increased tracer uptake without associated hypofixation.

Keywords:
Cerebral blood flow, Stroke, Single-photon computed emission tomography, Middle cerebral artery
1.
Fisher M: Characterizing the target of acute stroke therapy. Stroke 1997;28:866–872.
2.
Practice Advisory: Thrombolytic therapy for acute ischemic stroke – summary statement: Report of the Quality Standards Subcommitte of the American Academy of Neurology. Neurology 1996;47:835–839.
3.
Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245–1251.
4.
Lees KR: Does neuroprotection improve stroke outcome? Lancet 1998;351:1447–1448.
5.
Baron JC: Ischemic stroke: Cerebral blood flow, single-photon and positron emission tomography; in Ginsberg MD, Bogousslavsky J (eds): Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management. Oxford, Blackwell Science, 1998, vol 2, pp 1227–1240.
6.
Marchal G, Serrati C, Rioux P, Petit-Taboué MC, Viader F, de la Sayette V, Le Doze F, Lochon P, Derlon P, Orgogozo JM, Bardon JC: PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: Relation to outcome. Lancet 1993;341:925–927.
7.
Marchal G, Rioux P, Serrati C, Furlan M, Derlon P, Viader F, Baron JC: Value of acute-stage positron emission tomography in predicting neurological outcome after ischemic stroke Further assessment. Stroke 1995;26:524–525.
8.
Lee RGL, Hill TC, Holman BL, Royal HD, O’Leary DH, Clouse ME: Predictive value of perfusion defect size using N-isopropyl-(I-123)-p-iodoamphetamine emission tomography in acute stroke. J Neurosurg 1984;61:449–452.
9.
Lenzi GL, Giubilei F, Perani D, Di Piero V, Gerundini P, Pantano P, Argentino C, Fantozzi LM, Fazio F: Emission tomography: Functional follow-up studies in stroke. Circ Métab Cerv 1988;5:7–13.
10.
Hayman LA, Taber KH, Jhingran SG, Killian JM, Carroll RG: Cerebral infarction: Diagnosis and assessment of prognosis by using 123IMP-SPECT and CT. Am J Neuroradiol 1989;10:557–562.
11.
Giubilei F, Lenzi GL, Di Piero V, Pozzilli C, Pantano P, Bastianello S, Argentino C, Fieschi C: Predictive value of brain perfusion single-photon emission computed tomography in acute ischemic stroke. Stroke 1990;21:895–900.
12.
Limburg M, Van Royen EA, Hijdra A, De Bruine JF, Verbeeten BWJ: Single-photon emission computed tomography and early death in acute ischemic stroke. Stroke 1990;21:1150–1155.
13.
Davis SM, Chua MG, Lichtenstein M, Rossiter SC, Binns D, Hopper JL: Cerebral hypoperfusion in stroke prognosis and brain recovery. Stroke 1993;24:1691–1696.
14.
Jorgensen HS, Sperling B, Nakayama H, Raaschou HO, Olsen TS: Spontaneous reperfusion of cerebral infarcts in patients with acute stroke: Incidence, time course, and clinical outcome in the Copenhagen stroke study. Arch Neurol 1994;51:865–873.
15.
Lees KR, Weir CJ, Gillen GJ, Taylor AK, Ritchie C: Comparison of mean cerebral transit time and single-photon emission tomography for estimation of stroke outcome. Eur J Nucl Med 1995;22:1261–1267.
16.
Laloux P, Doat M, Brichant C, Cauwe F, Jamart J, De Coster P: Clinical usefulness of Technetium-99m HNMPAO SPECT imaging to map the ischemic lesion in acute stroke: A reevaluation. Cerebrovasc Dis 1994;4:280–286.
17.
Alexandrov AV, Black SE, Ehrlich LE, Bladin CE, Smurawska LT, Pirisi A, Caldwell CB: Simple visual analysis of brain perfusion on HMPAO SPECT predicts early outcome in acute stroke. Stroke 1996;27:1537–1542.
18.
Baird AE, Austin MC, McKay WJ, Donnan GA: Changes in cerebral tissue perfusion during the first 48 hours of ischaemic stroke: Relation to clinical outcome. J Neurol Neurosurg Psychiatry 1996;61:26–29.
19.
Bowler JV, Wade JPH, Jones BE, Nijran K, Steiner TJ: Single-photon emission computed tomography using hexamethylpropyleneamine oxime in the prognosis of acute cerebral infarction. Stroke 1996;27:82–86.
20.
Weir CJ, Bolster AA, Tytler S, Murray GD, Corrigall RS, Adams FG, Lees KR: Prognostic value of single-photon emission tomography in acute ischaemic stroke. Eur J Nucl Med 1997;24:21–26.
21.
Berrouschot J, Barthel H, Hesse S, Köster J, Knapp WH, Schneider D: Differentiation between transient ischemic attack and ischemic stroke within the first six hours after onset of symptoms by using 99mTc-ECD-SPECT. J Cereb Blood Flow Metab 1998;18:921–929.
22.
Orgogozo JM: Advantages and disadvantages of neurological scales. Cerebrovasc Dis 1998;8(suppl 2):2–7.
23.
Chang L: A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978;NS-25:638–643.
24.
Alexandrov AV, Ehrlich LE, Bladin CF, Black SE: Clinical significance of increased uptake of HMPAO on brain SPECT scans in acute stroke. J Neuroimaging 1996;6:150–155.
25.
Martinez-Vila E, Guillén F, Villanueva JA, Matias-Guiu J, Bigorra J, Gil P, Carbonell A, Martinez-Lage JM: Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction. Stroke 1990;21:1023–1028.
26.
Mountz JM, Modell JG, Foster NL, DuPree ES, Ackermann RJ, Petry NA, Bluemlein LE, Kuhl DE: Prognostication of recovery following stroke using the comparison of CT and Technetium-99m HM-PAO SPECT. J Nucl Med 1990;31:61–66.
27.
Marchal G, Rioux P, Serrati C, Furlan M, Lochon P, Derlon JM, Viader F, Baron JC: Imaging of cerebral blood flow and oxygen consumption in acute middle-cerebral artery stroke in humans: Further assessment of the predictive value for neurological course. Ann Neurol 1994;36:264–265.
28.
Laloux P, Richelle F, Jamart J, De Coster P, Laterre C: Comparative correlations of HMPAO SPECT indices, neurological score, and stroke subtypes with clinical outcome in acute carotid infarcts. Stroke 1995;26:816–821.
29.
Hanson SK, Grotta JC, Rhoades H, Tran HD, Lamki LM, Barron BJ, Taylor WJ: Value of single-photon emission-computed tomography in acute stroke therapeutic trials. Stroke 1993;24:1322–1329.
30.
Furlan M, Marchal M, Viader F, Derlon JM; Baron JC: Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol 1996;40:216–226.
31.
Yonekura Y, Nishizawa S, Mukai T, Fujita T, Fukuyama H, Ishikawa M, Kikuchi H, Konishi J, Andersen AR, Lassen NA: SPECT with 99mTc-d,1-hexamethyl-propylene amine oxime (HMPAO) compared with regional cerebral blood flow measured by PET: Effects of linearization. J Cereb Blood Flow Metab 1988;8(suppl):S82–S89.
32.
Gartshore G, Bannan P, Patterson J, Higley B, McCulloch J: Evaluation of technetium-99m exametazime stabilised with cobalt chloride as a blood flow tracer in focal cerebral ischaemia. Eur J Nucl Med 1994;21:913–923.
33.
Olsen TS, Larsen B, Skriver EB, Herning M, Enevoldsen E, Lassen NA: Focal cerebral hyperemia in acute stroke: Incidence, phatophysiology and clinical significance. Stroke 1981;12:598–607.
34.
Baird AE, Donnan GA: Prognostic value of reperfusion during first 48 hours of ischaemic stroke (letter). Lancet 1993;342:236.
35.
Shimosegawa E, Hatazawa J, Inugami A, Fujita H, Ogawa T, Aizawa Y, Kanno I, Okudera T, Uemura K: Cerebral infarction within six hours of onset: Prediction of completed infarction with technetium-99m-HMPAO SPECT. J Nucl Med 1994;35:1097–1103.
36.
Shintani S, Tsuruoka S, Satoh Y: Spurious hyperfixation of hexamethylpropyleneamine oxime in acute embolic stroke. Am J Neuroradiol 1995;16:1532–1535.
37.
Dierckx RA, Dobbeleir A, Pickut BA, Timmermans L, Direckx I, Vervaet A, Vandevivere J, Deberdt WE, De Deyn PP: Technetium-99m HMPAO SPET in acute supratentorial ischaemic infarction, expressing deficits as millilitre of zero perfusion. Eur J Nucl Med 1995;22:427–433.
38.
Shintani S, Tsuruoka S, Shiigai T: Paradoxial hyperfixation of hexamethylpropyleneamine oxime in cerebral infarction. AJNR 1997;18:1905–1908.
39.
Sperling B, Lassen NA: Hyperfixation of HMPAO in subacute ischemic stroke leading to spuriously high estimates of cerebral blood flow by SPECT. Stroke 1993;24:193–194.
40.
Oshima M, Tadokoro M, Sakuma S: Comparision of Tc-99m HMPAO fast SPECT with Tc-99m HMPAO conventional SPECT in patients with acute stroke. Clin Nucl Med 1992;17:18–22.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.